Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
congenital adrenal hyperplasia
Biotech
Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail
Spruce Biosciences' stock has shed three-quarters of its value in the wake of the failure of a phase 2 trial for the biotech's only drug candidate.
James Waldron
Mar 14, 2024 8:27am
Neurocrine's ph. 3 data set up 2024 hyperplasia drug submission
Oct 5, 2023 8:41am
Neurocrine's potential hyperplasia blockbuster scores ph. 3 win
Sep 12, 2023 10:18am
Spruce scores phase 2a win for rare disease drug, preps for 2020
Sep 19, 2019 8:00am
